NEFM

Across TCGA pan-cancer cohorts, NEFM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NEFM data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NEFM mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NEFM expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where NEFM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	IV	0.916	0.231	.024	8	view →
HNSC	OS	Median	All	0.957	1.000	.017	5	view →
GBM	OS	Tertile	All	0.184	0.425	.046	2	view →
CCRCC	OS	Median	III,IV	0.819	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NEFM–PDAC (OS)

Open the PDAC breakdown →